

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Aquarius Surgical Technologies Inc. (the "Issuer").

Trading Symbol: ASTI

Number of Outstanding Listed Securities: 18,233,545

Date: April 6, 2018

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer has scheduled two very influential clinical trials to begin in April; one for the flagship portable BPH laser and one for the newly introduced compact holmium laser. Both platforms have gained momentum in the marketplace subsequent to the Issuers recent marketing initiatives and

these two trials will provide additional data to support the clinical and operational value of the devices.

The BPH laser clinical trial, under the direction of the Chief of Urology of a university medical hospital in the northeast will focus on clinical efficacy and operational effectiveness of the procedure utilizing multiple delivery systems and anesthetic alternatives. The trial will comprise documented patient follow up to validate the outcomes. In conjunction with the trial, the Issuer is in conversation with university hospital regarding cooperative educational programs including the formation of a regional center of excellence and training facility for the portable BPH laser.

The compact holmium laser clinical trial, also scheduled to begin in April, will take place under the direction of a Professor of Urology and Biomedical Engineering of another major university hospital in the northeast. The institution is one of the foremost scientific and clinical reference points for holmium laser lithotripsy in North America. The first series of studies will involve parameter exploration with a standardized benchtop apparatus and begostone model with fragment distribution and fragmentation efficiency as outcome measures.

Subsequent to previous successful clinical trials with the compact holmium laser on patients, the objective of this further evaluation is to validate the operational efficiency and effectiveness experienced in those trials. Testing and evaluation will comprise maximum output performance on a variety of calculi types as well as maximum control associated with minimizing the risk of retropulsion and inadvertent stone migration. This additional data and formal documentation from a respected scientific and educational institution specializing in the science of laser lithotripsy will provide invaluable marketing support.

The compact holmium laser clinic trial is timely in that it corresponds to the availability of the Issuer's proprietary 'floating fiber' technology for the holmium laser. A fundamental component influencing the measurement of maximum performance and control, the new fiber is now available and shipping in limited quantities. A key differentiator in the holmium laser marketplace, the 'floating fiber' technology represents unique value and is the only technology of its kind available on the market today

2. Provide a general overview and discussion of the activities of management.

Senior Management of the Issuer also continued its capital raising program with the announcement of a Private Placement of Common share Equity Units to qualified investors, and subject to regulatory approvals.

Details of the Financing are available on Sedar, or directly from the Issuer.

Net proceeds will be used to purchase additional inventory, to continue promoting the issuers educational program, and for general corporate purposes.

Furthermore, the Issuer has commenced attending Investor Relations Firms sponsored High Net Worth retail broker meetings to further develop investor awareness which should lead to enhanced shareholder liquidity in due course.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None

8. Describe the acquisition of new customers or loss of customers.

None

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
None			

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None

16. Provide details of any changes in directors, officers or committee members.

None

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

No current changes

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 6, 2018

N. Gary Van Nest
Name of Director or Senior
Officer

Signed "Gary Van Nest"
Signature
Acting CEO
Official Capacity

Issuer Details Name of Issuer Aquarius Surgical Technologies Inc.	For Month End March 2018	Date of Report YY/MM/D 18/04/6
Issuer Address 89 Scollard Street		
City/Province/Postal Code Toronto, ON M5R 1G4	Issuer Fax No. (902)484-7599	Issuer Telephone No. (902) 496-7594
Contact Name Gary Van Nest	Contact Position Acting CEO	Contact Telephone No (647) 308-0685.
Contact Email Address gary@sinaltainvestments.com	Web Site Address www.surgicallasersinc.com	